Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Regional and temporal burden of liver cancer in Kazakhstan (2014–2023). حسب Ayana Ablayeva (22103708)

الموضوعات:

Upcycling of Postconsumer Recyclate Polypropylene into Low Warping and High Toughness 3D Printable Filaments حسب Animesh Gopal (18521180)

الموضوعات:

The difference of BMD between 2019 and 2022 classify by grop of urinary camium levels measured in 2019. حسب Aroon La-up (14095691)

الموضوعات:

Non-linear relationship between urinary cadmium and bone mineral density from the adjusted restricted cubic splines model. حسب Aroon La-up (14095691)

الموضوعات:

Prevalence of osteoporosis classified by sex, and urinary cadmium level compare between 2019 and 2022. حسب Aroon La-up (14095691)

الموضوعات:

Linear Mixed-Effects Model analysis of bone mineral density changes in relation to urinary cadmium levels in a 3-Year Period. حسب Aroon La-up (14095691)

الموضوعات:

Stratified analysis of the association between urinary cadmium and bone mineral density, by sex. حسب Aroon La-up (14095691)

الموضوعات:

Association between baseline urinary cadmium and the three-year change in bone mineral density (ΔBMD). حسب Aroon La-up (14095691)

الموضوعات:

Characteristics of the study participants for continuous variables. حسب Aroon La-up (14095691)

الموضوعات:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. حسب Claire M. Douglas (21238238)

الموضوعات:

Participant demographic and clinical characteristics. حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... حسب Claire M. Douglas (21238238)

الموضوعات:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... حسب Claire M. Douglas (21238238)

الموضوعات:

HDECO: A method for Decreasing energy and cost by using virtual machine migration by considering hybrid parameters حسب Arash GhorbanniaDelavar (22563696)

"…</p><p dir="ltr">Compared to the ECIB algorithm and previous approaches, HDECO achieved significant improvements:</p><ul><li><b>Up to 10% reduction in energy consumption</b></li><li><b>8% decrease in overall execution cost</b></li><li><b>Better real execution time and fewer unnecessary migrations</b></li></ul><p dir="ltr">This makes HDECO an effective and lightweight solution for instance-intensive cloud workflows.…"